Veterinary Antibiotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The veterinary antibiotics market size was valued at USD 5.40 billion in 2025 and is estimated to grow from USD 5.55 billion in 2026 to reach USD 6.36 billion by 2031, at a CAGR of 2.75% during the forecast period. This report is Segmented by Animal Type (Poultry, and More), Drug Class (Tetracyclines, and More), Delivery Form (Premixes, and More), Spectrum of Activity (Broad-Spectrum and More), End User (Food-Producing Animal Producers and More), Distribution Channel (Veterinary Hospitals and More), and Geography (North America, Europe, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Veterinary Antibiotics Market Trends and Insights

Surging Global Demand for Animal-Source Protein Post-Pandemic

Global meat output rebounded in 2025 with poultry volumes up 4.2% and pork up 3.8% as restaurants reopened and exports recovered. Producers in Asia-Pacific and Latin America expanded intensive operations to serve China and Middle Eastern importers, increasing prophylactic antibiotic use in broiler and finishing pig systems. Developed markets are channelling growth into narrow-spectrum, prescription-only therapies, whereas emerging economies still rely on over-the-counter broad-spectrum formulations. This demand bifurcation is shifting volume from highly regulated regions to countries with limited enforcement, sustaining baseline growth for the veterinary antibiotics market. However, mounting scrutiny from global retailers is pressuring exporters to adopt stewardship protocols, accelerating the transition to animal-only molecules.

Rebound in Companion-Animal Ownership & Veterinary Expenditure

The United States recorded 67% household pet ownership in 2025, up four percentage points from 2023, and per-pet veterinary spend rose 6.1% annually during 2024-2025. Similar patterns emerged in Europe and urban Asia-Pacific. Diagnostics-guided prescribing in clinics is favouring aminoglycosides and first-generation cephalosporins, narrowing demand for broad-spectrum fluoroquinolones. Online pharmacies linked to tele-veterinary platforms are capturing prescription refills, although state-level telemedicine rules in the U.S. and cross-border licensing limits in the EU temper the scale. The resulting growth in the companion sector underpins premium pricing resilience for the veterinary antibiotics market.

Other drivers and restraints analyzed in the detailed report include:

• Regulatory Shift Toward Animal-Only Antibiotic Classes
• Expansion of Injectable, Heat-Stable Long-Acting Formulations in Ruminants
• Tightening AMR Regulations Reducing Group Treatments
• Rapid Penetration of Probiotic / Phage Growth-Promoter Alternatives

Segment Analysis

The veterinary antibiotics market for poultry accounted for 32.55% of global revenue. Regulatory pressure in the EU and North America is capping prophylactic usage, and ionophore substitution is maturing. In contrast, aquaculture generated only USD 0.62 billion but is advancing at a 6.85% CAGR as Southeast Asian shrimp and tilapia farms continue unmonitored antibiotic dosing. The divergence underscores how enforcement intensity steers volume across species.

Growth in aquaculture is driven by high disease incidence and limited approved fish-specific formulations, prompting farmers to use livestock drugs off-label. Swine demand remains steady as precision-dose pleuromutilins replace bulk tetracyclines, and cattle uptake is bifurcated between long-acting injectables in beef feedlots and intramammary tubes in dairies. Companion-animal antibiotic sales climb on the back of rising pet ownership, with aminoglycosides gaining share for urinary tract infections. Sheep and goats remain niche, reflecting limited commercial farming outside the Mediterranean and Middle-East belts.

Tetracyclines accounted for 28.53% of 2025 revenue, making them the largest share of the veterinary antibiotics market. Wastewater discharge limits and feed directives, however, are trimming metaphylactic use. Aminoglycoside revenue stood at USD 0.68 billion and is set to grow at a 6.75% CAGR to 2031, as veterinarians favor gentamicin and amikacin for companion-animal respiratory and urinary infections.

Penicillins and first-generation cephalosporins sustain demand in dairy mastitis protocols, while third-generation cephalosporins face “reserve” designations. Macrolides, spearheaded by tulathromycin, gain in bovine respiratory disease owing to long-acting injectables. Fluoroquinolone volumes contract following aquaculture bans in China and tightened EU rules, and sulfonamide share erodes as combination therapies pack higher efficacy at lower doses.

Complete Report Scope:

• By Animal Type
  • Poultry
  • Swine
  • Cattle
  • Sheep & Goats
  • Companion Animals
  • Aquaculture
  • Other Livestock
• By Drug Class
  • Tetracyclines
  • Penicillins
  • Sulfonamides
  • Macrolides
  • Aminoglycosides
  • Cephalosporins
  • Fluoroquinolones
  • Others
• By Delivery Form
  • Premixes
  • Oral Powders
  • Oral Solutions
  • Injections
  • Intramammary & Intra-uterine
  • Feed-Additive Blends
• By Spectrum of Activity
  • Broad-Spectrum
  • Narrow-Spectrum
• By End User
  • Food-Producing Animal Producers
  • Companion-Animal Owners
• By Distribution Channel
  • Veterinary Hospitals & Clinics
  • Retail Pharmacies
  • Online Channels
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America, accounting for 32.52% of 2025 revenue, is expected to decline due to veterinary feed directive curbs on over-the-counter sales and a rural veterinarian shortage, which limits prescription bandwidth. Nevertheless, premium companion-animal spending and uptake of long-acting injectables for feedlot cattle underpin stable margins.

Asia-Pacific projected to climb 6.12% CAGR to 2031. China’s genotyping mandates and India’s dairy upgrades lift narrow-spectrum demand, while under-regulated aquaculture corridors in Southeast Asia continue broad-spectrum purchases via informal networks. Regulatory gaps facilitate volume growth but raise residual risks for exporters facing stricter EU entry requirements.

Europe is navigating aggressive AMR and wastewater standards that elevate compliance costs. Generic manufacturer consolidation is underway, as smaller firms exit rather than fund EUR 0.2-0.5 million ERA dossiers. Latin America records varied trajectories: Brazil’s export-oriented integrators align with importing-country protocols, while domestic producers continue to use OTC. The Middle East and Africa together contribute significant revenue but remain fragmented; Gulf states import premium formulations, whereas sub-Saharan markets depend on generics sold through co-ops with limited vet oversight.

List of Companies Covered in this Report:

• AdvaCare Pharma LLP
• Ashish Life Science Private Limited
• Bimeda Holdings Limited
• Boehringer Ingelheim Animal Health International GmbH
• Ceva Sante Animale S.A.
• Chanelle Pharma Private Limited
• Dechra Pharmaceuticals Limited
• Elanco
• HIPRA, S.A
• Huvepharma
• KRKA d.d.
• Kyoritsu Seiyaku
• Merck Animal Health (MSD)
• Norbrook
• Ourofino Saúde Animal
• Phibro Animal Health
• Vetoquinol
• Virbac
• Zoetis
• Zydus Animal Health

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support